Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Interstitial lung disease
What were your Top Takeaways in ILD from ACR Convergence 2025?
Related Questions
Is it still significant to denote the etiology of ILD in a patient with PPF?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
How would you approach rituximab dosing in a patient with SLE-Myositis overlap with LN Class III, now with worsening UPCR and concern for worsening ILD 4 months post induction and incomplete B-Cell depletion on recent labs?
How do you approach management of chronic cough in patients with ILD?
How frequently do you monitor CT scans, PFTs, and TTEs in patients with ILA or mild ILD?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
How do you approach prescribing analgesics for osteoarthritis related pain in patients with comorbidities, particularly given new evidence that even acetaminophen is associated with increased risk of GI complications (bleeding, peptic ulcer disease), heart failure and CKD?
Is it safe to use one TNF inhibitor (e.g., infliximab) in a patient who has had a severe allergic reaction to a different TNF inhibitor (e.g., adalimumab)?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
Can cryoglobulins be present in the setting of severe acrocyanosis without evidence of active cryoglobulinemic vasculitis?
